Stock Track | Protagonist Therapeutics Soars 7.57% in Pre-Market on Bullish Analyst Views of Pipeline and Partnerships

Stock Track

02/24

Protagonist Therapeutics (PTGX) stock surged 7.57% in pre-market trading on Monday, fueled by a reiterated Buy rating from BMO Capital analyst Etzer Darout. The analyst cited the company's promising pipeline and strategic partnerships as key growth drivers.

Darout expressed optimism about Protagonist's pipeline and collaborations, noting their potential to drive significant shareholder value in the coming years. The positive analyst coverage boosted investor sentiment, pushing the stock higher ahead of the market open.

Additionally, HC Wainwright maintained its Buy rating on Protagonist Therapeutics, reflecting sustained positive analyst sentiment toward the company's prospects. Investors will be closely watching for further developments from Protagonist's pipeline and partnership efforts.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1156089858"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1156089858\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1156089858?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-24 21:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1156089858","market":"us","top_or_hot":-1,"title":"Stock Track | Protagonist Therapeutics Soars 7.57% in Pre-Market on Bullish Analyst Views of Pipeline and Partnerships","media":"Stock Track","content":"<p>Protagonist Therapeutics (PTGX) stock surged 7.57% in pre-market trading on Monday, fueled by a reiterated Buy rating from BMO Capital analyst Etzer Darout. The analyst cited the company's promising pipeline and strategic partnerships as key growth drivers.</p>\n\n<p>Darout expressed optimism about Protagonist's pipeline and collaborations, noting their potential to drive significant shareholder value in the coming years. The positive analyst coverage boosted investor sentiment, pushing the stock higher ahead of the market open.</p>\n\n<p>Additionally, HC Wainwright maintained its Buy rating on Protagonist Therapeutics, reflecting sustained positive analyst sentiment toward the company's prospects. Investors will be closely watching for further developments from Protagonist's pipeline and partnership efforts.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Protagonist Therapeutics Soars 7.57% in Pre-Market on Bullish Analyst Views of Pipeline and Partnerships</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Protagonist Therapeutics Soars 7.57% in Pre-Market on Bullish Analyst Views of Pipeline and Partnerships\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2025-02-24 21:02</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Protagonist Therapeutics (PTGX) stock surged 7.57% in pre-market trading on Monday, fueled by a reiterated Buy rating from BMO Capital analyst Etzer Darout. The analyst cited the company's promising pipeline and strategic partnerships as key growth drivers.</p>\n\n<p>Darout expressed optimism about Protagonist's pipeline and collaborations, noting their potential to drive significant shareholder value in the coming years. The positive analyst coverage boosted investor sentiment, pushing the stock higher ahead of the market open.</p>\n\n<p>Additionally, HC Wainwright maintained its Buy rating on Protagonist Therapeutics, reflecting sustained positive analyst sentiment toward the company's prospects. Investors will be closely watching for further developments from Protagonist's pipeline and partnership efforts.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PTGX","symbol_name":"Protagonist Therapeutics Inc","start_time":0,"source_url":"","article_id":"1156089858","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1156089858","pubTimestamp":1740402168,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Protagonist Therapeutics  stock surged 7.57% in pre-market trading on Monday, fueled by a reiterated Buy rating from BMO Capital analyst Etzer Darout. The analyst cited the company's promising pipeline and strategic partnerships as key growth drivers.Darout expressed optimism about Protagonist's pipeline and collaborations, noting their potential to drive significant shareholder value in the coming years. The positive analyst coverage boosted investor sentiment, pushing the stock higher ahead of","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PTGX":"Protagonist Therapeutics Inc"},"translate_title":"由于分析师对管道和合作伙伴关系的乐观看法，股票赛道主角Therapeutics盘前飙升7.57%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PTGX":1},"content_text":"Protagonist Therapeutics (PTGX) stock surged 7.57% in pre-market trading on Monday, fueled by a reiterated Buy rating from BMO Capital analyst Etzer Darout. The analyst cited the company's promising pipeline and strategic partnerships as key growth drivers.\nDarout expressed optimism about Protagonist's pipeline and collaborations, noting their potential to drive significant shareholder value in the coming years. The positive analyst coverage boosted investor sentiment, pushing the stock higher ahead of the market open.\nAdditionally, HC Wainwright maintained its Buy rating on Protagonist Therapeutics, reflecting sustained positive analyst sentiment toward the company's prospects. Investors will be closely watching for further developments from Protagonist's pipeline and partnership efforts.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}